Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.

Molecular cancer - 7 Jun 2010

Hsu Yi-Fan, Ajona Daniel, Corrales Leticia, Lopez-Picazo Jose M, Gurpide Alfonso, Montuenga Luis M, Pio Ruben

Abstract excerpt

BACKGROUND: Cetuximab, an antibody targeting the epidermal growth factor receptor (EGFR), increases survival in patients with advanced EGFR-positive non-small cell lung cancer when administrated in combination with chemotherapy. In this study, we investigated the role of complement activation in the antitumor mechanism of this therapeutic drug. RESULTS: EGFR-expressing lung cancer cell lines were able to bind...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cetuximab

Share to Complement Activation

Share to Fluorescent Antibody Technique

Share to Mice, Nude

Share to ras Proteins

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 20529262
DOI: 10.1186/1476-4598-9-139
PMCID: PMC2893457

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.PMID 20529262Read ↗

The complement system as a target in cancer immunotherapySemantic proximity Read ↗

Complement as a Biological Tool to Control Tumor GrowthSemantic proximity Read ↗

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancerSemantic proximity Read ↗

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.Semantic proximity Read ↗

Complement Is a Central Mediator of Radiotherapy-Induced Tumor-Specific Immunity and Clinical ResponseSemantic proximity Read ↗

Complement as effector system in cancer immunotherapySemantic proximity Read ↗

Complement-Activating Multimeric Immunotherapeutic Complexes for HER2-breast cancer immunotherapySemantic proximity Read ↗

Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancerSemantic proximity Read ↗

Activation of the complement system in an osteosarcoma cell line promotes angiogenesis through enhanced production of growth factorsSemantic proximity Read ↗

Targeting CD137 enhances the efficacy of cetuximab.Semantic proximity Read ↗

Supra-additive cytotoxic effects of a combination of cytostatic drugs and antibody-induced complement activation on tumor cells in vitro.Semantic proximity Read ↗

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.